Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.